Weak antioxidant capacity, particularly low catalase activity in the heart, may be a factor responsible for the high sensitivity of this organ to doxorubicin-induced oxidative damage. To test this hypothesis, a heart-specific promoter was used to drive the expression of murine catalase cDNA in transgenic mice. Fifteen healthy transgenic mouse lines were produced. Cardiac catalase activity was constitutively overexpressed in both atrium and ventricle, ranging from 2-to 630-fold higher than normal. This enzyme activity was not altered in liver, kidneys, lungs, and skeletal muscles. Other antioxidant components, including glutathione, glutathione peroxidase, glutathione reductase, metallothionein, and superoxide dismutase, were not altered in the catalaseoverexpressing heart. Mice (7 weeks old) from several transgenic lines and from nontransgenic controls were treated intraperitoneally with doxorubicin at a single dose of 20 mg/kg and sacrificed on the 4th day after treatment. As compared to normal controls, transgenic lines expressing catalase activity 60-or 100-fold higher than normal exhibited a significant resistance to doxorubicin-induced cardiac lipid peroxidation, elevation of serum creatine phosphokinase, and functional changes in the isolated atrium. Interestingly, 200-fold or greater elevation of catalase activity did not provide protection. The results provide direct evidence for the role of catalase in doxorubicin cardiotoxic responses.
Weak antioxidant capacity, particularly low catalase activity in the heart, may be a factor responsible for the high sensitivity of this organ to doxorubicin-induced oxidative damage. To test this hypothesis, a heart-specific promoter was used to drive the expression of murine catalase cDNA in transgenic mice. Fifteen healthy transgenic mouse lines were produced. Cardiac catalase activity was constitutively overexpressed in both atrium and ventricle, ranging from 2-to 630-fold higher than normal. This enzyme activity was not altered in liver, kidneys, lungs, and skeletal muscles. Other antioxidant components, including glutathione, glutathione peroxidase, glutathione reductase, metallothionein, and superoxide dismutase, were not altered in the catalaseoverexpressing heart. Mice (7 weeks old) from several transgenic lines and from nontransgenic controls were treated intraperitoneally with doxorubicin at a single dose of 20 mg/kg and sacrificed on the 4th day after treatment. As compared to normal controls, transgenic lines expressing catalase activity 60-or 100-fold higher than normal exhibited a significant resistance to doxorubicin-induced cardiac lipid peroxidation, elevation of serum creatine phosphokinase, and functional changes in the isolated atrium. Interestingly, 200-fold or greater elevation of catalase activity did not provide protection. The results provide direct evidence for the role of catalase in doxorubicin cardiotoxic responses.
Doxorubicin is an anthracycline antibiotic and one of the most important anti-cancer agents. It is effective in treatment of acute leukemias and malignant lymphomas as well as a number of solid tumors. However, the clinical use of doxorubicin is limited by its cardiotoxicity (1) (2) (3) . Studies have suggested that doxorubicin may have at least two mechanisms of action that cause cellular damage. One mechanism involves generation of oxygen free radicals, the damage from which is inhibited by free radical scavengers. This appears to play a major role in the development of cardiomyopathy (4 -7) . The other mechanism is mediated by the intercalation of the drug to DNA and is unaffected by free radical scavengers. This appears to be the major determinant of doxorubicin cytotoxicity to tumor cells (7) .
Catalase is a major enzyme involved in the detoxification of hydrogen peroxide (H 2 O 2 ). This enzyme catalyzes the conversion of two molecules of H 2 O 2 to molecular oxygen and two molecules of water. The primary physiological function of this enzyme is to detoxify the H 2 O 2 produced as a result of peroxisomal aerobic dehydrogenase reactions. The importance of catalase in providing protection against extraperoxisomal H 2 O 2 is not clear. Studies with isolated hepatocytes, however, have demonstrated that, under conditions of GSH depletion, catalase functions in the metabolism of H 2 O 2 produced by the cytochrome P-450-linked monooxygenase system (8) . It is thus possible that, under conditions of extreme oxidative stress, which in most cases involves GSH depletion, catalase may become important in providing cytoprotection.
Catalase activities are highest in liver and erythrocytes, relatively high in kidney and adipose tissue, intermediate in lung and pancreas, and very low in heart and brain (9) . It has been shown that catalase activity in the heart is about 2% of that in the liver of the human (9), the mouse (10), and the rat (11) . Several studies have been undertaken to determine the role of catalase in cardioprotection against oxidative injuries. Supplementation of perfusion medium with catalase significantly reduced ischemia-reperfusion injury to the isolated rat heart by detoxifying H 2 O 2 (12) . The role of catalase in metabolism of H 2 O 2 in the heart tissue was also tested directly by adding H 2 O 2 into perfusion medium (13) . Accumulated evidence shows that catalase, although present at low levels of activity, functions in detoxification of H 2 O 2 in the myocardium.
It is unknown, however, whether the low catalase activity in the heart is responsible for the high sensitivity of this organ to oxidative stress. Current approaches using the isolated heart perfused with catalase have limited application. Exogenously added catalase may not be able to function intracellularly, but may react only with H 2 O 2 directly in the perfusion medium. Thus, the relationship between the low constitutive catalase activity and the high sensitivity to oxidative stress in the heart has not been defined. A unique in vivo model is required to overcome these limitations and to precisely determine the role of catalase in protection against oxidative cardiotoxicity.
In the present study, we have developed a transgenic mouse model in which catalase is overexpressed only in the heart. To determine whether catalase elevation provides protection against doxorubicin cardiotoxicity, lipid peroxidation in the heart and serum creatine phosphokinase (CPK) 1 activity were measured in the doxorubicin-treated transgenic mice and nontransgenic controls. In addition, the atria isolated from the transgenic mice and nontransgenic controls were used to determine the effect of catalase on doxorubicin-induced functional changes. The results demonstrate that overexpression of catalase in the heart provides protection against doxorubicin cardiotoxicity.
MATERIALS AND METHODS

Generation and Identification of Cardiac Catalase Overexpressing Transgenic Mice
FVB mice obtained from the University of North Dakota Biomedical Research Center were used to produce transgenic lines. All animal procedures were approved by the American Association of Accreditation of Laboratory Animal Care certified institutional animal care committee. An 8-kb pair transgene designated MyCat, was constructed for overexpression of catalase in cardiac tissue of transgenic mice (Fig. 1) . This transgene contains all of the coding sequences of the rat catalase cDNA (14) . Transcription of the transgene is controlled by a fragment of the mouse alpha cardiac myosin heavy chain (MHC) gene previously used by Gulick et al. (15) to produce high level, cardiac-specific expression of cDNA constructs in transgenic mice. A 1730-bp NcoI/HindIII fragment of the rat catalase cDNA (14) which included the catalase start and stop codons was ligated behind a 5.7-kb BamHI/SalI fragment of the MHC gene. The MHC fragment includes the MHC promoter, the first two introns, and the first three noncoding exons of the MHC gene (15) . To provide NotI restriction sites for purification of the transgene and to add a polyadenylation signal for the catalase transcript the 7430-bp BamHI/HindIII fragment containing the MHC promoter and catalase coding sequence was ligated in front of a 550-bp SmaI/ApaI fragment of the rat insulin II gene containing the insulin polyadenylation sequence (16) . The ApaI site of this insulin fragment had previously been converted to a NotI site using NotI linkers and an additional NotI site was contained in a polylinker upstream of the insulin fragment.
Standard procedures (17) were employed for development of transgenic mice. The 8-kb MyCat transgene (the NotI fragment, Fig. 1 ) was purified (18) on a matrix of diatemaceous earth (Prepagene, Bio-Rad) and filtered through a 0.22-m filter. Approximately 100 copies of the purified transgene insert were microinjected into one pronucleus of each one-cell mouse embryo of the inbred strain FVB (19) . Twenty microinjected embryos were implanted into each Avertin-anesthetized pseudopregnant female and allowed to come to term. To identify transgenic founder mice, genomic DNA was isolated from 1-cm tail clips from 3-4-wk-old mice. DNA was subjected to Southern and dot blot analyses which were probed with a 550-bp SmaI/NotI fragment derived from the rat insulin II portion (16) of the MyCat transgene. This probe hybridized to an 8000-bp EcoRI fragment of the transgene, consistent with the presence of a unique EcoRI site in the MyCat transgene (600 bp upstream of the MHC transcription initiation site) (15) . Founder mice were bred with mice of the same strain and transgenic offspring were routinely identified by a polymerase chain reaction using a primer pair derived from the MHC promoter and rat catalase cDNA. Transgenic positive mice (heterozygotes) and negative littermates were then used for experiments.
Molecular and Biochemical Analyses
Preparation of Tissue Samples-Animals were anesthetized with an intraperitoneal injection of sodium pentobarbital (65 mg/kg body weight, Vet Labs, Lenexa, KS). To avoid the contribution of the red blood cells remaining in the heart to the measured parameters, the heart of anesthetized mice was perfused with 20 ml of saline (room temperature). A cannulated needle (25G3/8) was inserted about 3 mm into the left ventricle. The inferior vena cava was punctured to allow blood and saline to wash out. The heart was then removed. The liver, lung, and kidney were excised and flushed with cold saline via their major vessels. Tissue samples were placed in liquid nitrogen and then stored at Ϫ80°C for less than 36 h before analyses as described below.
Northern Blot Analysis-Total RNA was extracted from the myocardium tissue using the RNazol B method (Cinna/Biotex). RNA was quantified spectrophotometrically and confirmed by ethidium bromide staining of 18 and 28 S ribosomal RNA. RNA was denatured in formaldehyde, fractionated by electrophoresis on 1.0% agarose gels, and transferred to nylon membranes. The probe corresponding to a 900-base HindIII and BglII fragment of the rat catalase cDNA (14) (Fig. 1 ) was randomly labeled with [␣-32 P]dCTP (DuPont NEN) using the Klenow fragment of DNA polymerase I (Life Technologies, Inc.) and purified by chromatography (Sephadex G-50, Sigma) before hybridization. Hybridization and wash procedures were conducted using previously published methods. Autoradiographic images were scanned and analyzed using the MCID system from Imaging Research Inc. (Ontario, Canada).
Catalase-The tissues were homogenized in 1.0% Triton X-100 using a variable speed tissue tearer (Biospec Products, Inc.) at about 20,000 rpm for 30 s on ice. The homogenates were centrifuged at 10,000 rpm at 4°C for 20 min. The supernatant was diluted with 1.5 volumes of the assay buffer (50 mM KH 2 PO 4 /50 mM NaH 2 PO 4 , pH 7.0). The enzyme activity was determined by the method described by Aebi (20) . Briefly, in a cuvette 2 ml of sample were added. The reaction was initiated by adding 1.0 ml of 30 mM H 2 O 2 , and the change in absorbance at 240 nm was monitored at 25°C for 1.0 min. A portion of the remaining sample was used for protein determination. Specific activity is expressed as mol H 2 O 2 /min/mg of protein. Protein was determined by the method of Smith et al. (21) using bovine serum albumin as the standard.
GSH Peroxidase-Tissue samples were prepared as described above with the exception of the assay buffer (0.1 M KH 2 PO 4 , 1 mM EDTA, pH 7.0). The enzyme activity was determined by the method described by Flohe and Gunzler (22) . In 5 ml of assay tubes, 500 l of buffer containing 2 mM sodium azide, 100 l of GSH (10 mM), 100 l of GSH reductase (2.4 units/ml), and 100 l of sample were incubated for 10 min in 37°C water bath, then 100 l of NADPH (1.5 mM) was added, and the reaction mixture was transferred to cuvettes. Absorbance at 340 nm was monitored at 37°C for 3 min before 100 l of prewarmed H 2 O 2 (1.5 mM) were added, followed by an additional 5-min monitoring under the same conditions. Enzyme activity was calculated as described previously (22) . Specific activity is expressed as nanomoles of NADPH/ min/mg of protein.
GSH Reductase-The enzyme activity was determined by the method described by Carlberg and Mannervik (23) . The tissue preparations were the same as described above for GSH peroxidase. The assay buffer was 0. (15) . Lines between the boxes designate two MHC introns. The open box designates the rat catalase cDNA (14) , and the slashed box indicates the portion of the transgene derived from the rat insulin II gene (16) . Arrow 1 shows the position of the transcription initiation site of the alpha cardiac MHC gene. Arrows 2 and 3 show the positions of the native start and stop codons of rat catalase. Arrow 4 indicates the position of the polyadenylation sequence from the rat insulin II gene. Restriction sites used to construct the transgene, to purify the transgene, or to obtain probes are indicated. Restriction sites shown in parentheses were destroyed during construction of MyCat. The bars designated as A and B indicate the portions of the transgene which were used to prepare probes of the Northern and Southern blots, respectively. 37°C for 2 min. The enzyme activity was calculated as described elsewhere (23) . Specific activity is expressed as nanomoles of NADPH/ min/mg of protein.
Superoxide Dismutase (SOD)-The enzyme activity was assayed as described by Nebot et al. (24) . This method is based on the fact that the rate of alkaline autoxidation of 5,6,6a,11b-tetrahydro-3,9,10-trihydroxybenzo[c]fluorene (BXT-01050) is accelerated by SOD activity. This autoxidation yields a chromophore which is detected at 525 nm. A SOD-525 assay kit based on this method was obtained from BioxyTech S.A., France. Briefly, tissue samples were homogenized in 9 volumes of 0.25 M sucrose solution. The homogenate was centrifuged at 1,400 ϫ g for 5 min at 4°C. A 250-l aliquot of the supernatant was dialyzed against distilled water at 4°C with a M r 12,000 exclusion membrane for 24 h. The sample was then mixed with a mercaptan scavenger, 1,4,6-trimethyl-2-vinylpyridinium, for 1 min to eliminate major mercaptan interferences. Total SOD (Cu,Zn-SOD and Mn-SOD) activity was determined colorimetrically immediately following addition of the chromogenic reagent, BXT-01050. One SOD-525 activity unit is defined as the activity that doubles the BXT-01050 autoxidation background (24) . The enzyme activity is expressed as units/g of wet tissue.
GSH and GSH Disulfide-Tissues were homogenized in 10 volumes of 5% (w/v) 5-sulfosalicylic acid at 4°C. The homogenate was centrifuged at 10,000 ϫ g for 15 min, and the supernatant was assayed for GSH by the DTNB-glutathione reductase recycling assay (25) . The 1.0-ml reaction mixture contained 190 l of stock buffer (143 mM sodium phosphate and 6.3 mM Na 4 -EDTA, pH 7.5), 700 l of 0.248 mg NADPH/ml in stock buffer, 100 l of 6 mM DTNB, and 10 l of sample. The assay was initiated by addition of 10 l of 266 units of glutathione reductase/ml. Standards were assayed in parallel under the same conditions as tissue samples.
Metallothionein (MT)-Total tissue MT concentrations were determined by the cadmium-hemoglobin affinity assay (26) . Briefly, tissues were homogenized in 4 volumes of 10 mM Tris-HCl buffer, pH 7.4, at 4°C. Following centrifugation of the homogenate at 10,000 ϫ g for 15 min, 200 l of supernatant were transferred to microtubes for MT analysis, and 100 l were transferred to separate microtubes for protein analysis. Samples were then prepared for MT determination as described previously (26) .
Determination of Doxorubicin Cardiotoxicity
Transgenic mice and normal controls (7 weeks old, without regard to sex because our preliminary studies showed no difference in cardiac toxic responses to doxorubicin between males and females) were injected intraperitoneally with doxorubicin hydrochloride (Sigma) at 20 mg/kg. Four days after receiving the doxorubicin injection, the experimental animals were anesthetized intraperitoneally with sodium pentobarbital (65 mg/kg body weight, Vet Labs, Lenexa, KS), and cardiotoxicity was determined as described below.
Lipid Peroxidation-Hearts were rapidly excised, trimmed of connecting tissue, and washed free of blood with ice-cold saline. They were then blotted and weighed. Temperature was maintained at 4°C throughout the experiment. Because the classical malondialdehyde (MDA) determination by the thiobarbituric-acid method is influenced by several interferences and its reproducibility is not satisfactory (27) , a modified assay was used in the present study (28) . This modified method measures the products of lipid peroxidation, MDA, and 4-hydroxyalkenal. A commercial kit based on this method was used (LPO-586, BioxyTech S.A., France).
CPK Activity-Serum CPK activity was assayed as described by Oliver (29) . A CPK test kit (CK-20, Sigma) based on this method was obtained from Sigma. Blood was collected from the inferior vena cava of the anesthetized animals, and serum was obtained by a serum separator apparatus (Becton Dickinson, Rutherford, NJ).
Atrial Functional Alteration-Mice were anesthetized with sodium pentobarbital. Atria were separated from ventricles and placed in a 30-ml chamber containing Krebs-Henseleit (KH) buffer of the following composition: NaCl (118 mM), KCl (4.7 mM), NaHCO 3 (3.0 mM), CaCl 2 (3.0 mM), MgSO 4 (1.2 mM), KH 2 PO 4 (1.2 mM), glucose (10 mM), Na 2 EDTA (0.5 mM), pH 7.4, gassed with 5% CO 2 in O 2 . A preload tension of 0.25 g was applied. The atria were allowed to stabilize for 30 min before doxorubicin was added to the incubation buffer to a final concentration of 100 M. Changes in spontaneous contraction were recorded isometrically by a Grass FT.03 force transducer and a Grass 7 recorder (Grass Instrument Co., Quincy, MA). The effect of doxorubicin on inotropy (contractile force) and chronotropy (heart rate) were determined using isolated left and right atrium, respectively.
RESULTS
Cardiac catalase activity was analyzed in six animals (three males and three females) of each transgenic line and nontransgenic controls. As shown in Fig. 2 , catalase activity was markedly elevated in the transgenic hearts. This elevation ranges from 2-fold in line 786 to 630-fold in line 784. There was no significant difference (p Ͼ 0.10) in the catalase activity between males and females within the same transgenic line (data not shown). The level of mRNA for catalase was also increased in the transgenic heart as shown in Fig. 3 . This overexpression was rather stable as evidenced by consistent results obtained in several assays performed over one year. The results clearly demonstrate that the increased catalase activity results from expression of the MyCat transgene. We tested whether the catalase activity is elevated to the same extent in both atria and ventricles. As shown in Fig. 4 , the elevated catalase activity was the same in atria and ventricles from five representative transgenic mouse lines. We also determined whether the elevated catalase expression was specific to the heart. Catalase activities in liver, kidneys, lungs, and skeletal muscles of the transgenic mice were measured. As shown in Fig. 5 , catalase activities in all of these tissues were the same as that of controls.
We then determined whether other antioxidant enzyme activities in the transgenic heart were altered due to changes in catalase activity. The activities of SOD, GSH peroxidase, and GSH reductase were measured in the catalase-enriched transgenic hearts. As shown in Table I , none of these enzyme activities was changed. We also measured the concentrations of two important nonenzymatic antioxidant components, GSH and MT. There is no alteration in either of the two components in the catalase-enriched transgenic hearts (Table I ).
Four transgenic lines were then selected to determine the effect of elevated catalase activity on doxorubicin-induced oxidative damage to the heart. These four transgenic lines have cardiac catalase activity about 15-, 60-, 100-, and 200-fold higher than normal. Transgenic mice and nontransgenic controls were treated with a single dose of doxorubicin at 20 mg/kg. Four days after the treatment, the lipid peroxide products, MDA, and 4-hydroxyalkenals were determined. As shown in Fig. 6 , the level of the lipid peroxidation products was markedly elevated by doxorubicin in nontransgenic mice. Overexpression of catalase suppressed this effect of doxorubicin in a catalase activity-dependent fashion. The highest protection was observed in the hearts expressing this enzyme activity about 60 -100-fold higher than normal. However, the transgenic line overexpressing catalase activity about 200-fold higher than normal demonstrated no protection from doxorubicin.
Doxorubicin toxicity was also revealed by elevated serum CPK in nontransgenic mice (Fig. 7) . Catalase overexpression provided essentially the same protection against CPK release as it did for lipid peroxidation. Again, the protection was roughly activity dependent except for the line with 200-fold overexpression, which failed to demonstrate any protection.
Because the loss of protection with 200-fold overexpression of catalase activity was unexpected, we performed preliminary studies with 500-fold catalase overexpressing mice (line 756). The doxorubicin increased MDA levels to 93.1 Ϯ 10.9 nmol/g (n ϭ 4) in the transgenic heart and 80.6 Ϯ 2.2 nmol/g (n ϭ 4) in the nontransgenic heart. The level of serum CPK was 1.70 Ϯ 0.15 units/ml (n ϭ 4) in the doxorubicin-treated transgenic mice and 1.54 Ϯ 0.20 units/ml (n ϭ 4) in the doxorubicintreated nontransgenic mice. These preliminary results suggested that 500-fold higher levels of catalase may have enhanced doxorubicin-induced lipid peroxidation in the heart and Fig. 4 (lines 738, 742, 782, 776, 777) . The values represent the pooled data from the five lines with three determinations of each line (mean Ϯ S.D., n ϭ 15) for MyCat and from six control animals (Cont).
TABLE I Enzyme activities of SOD, GSH peroxidase, and GSH reductase, and concentrations of GSH and MT in the hearts of control and MyCat transgenic mice
The data were obtained from nontransgenic mice (control, n ϭ 6) and five representative transgenic mouse lines as shown in Fig. 4 (lines 738,  742 , 782, 776, and 777). Three mice were used from each of the five lines and the data were pooled together to give the average value (MyCat, n ϭ 15). CPK release from the heart. Isolated atria from transgenic mice overexpressing cardiac catalase about 60-fold were used to determine the effect of doxorubicin on atrial function. Spontaneous contractions were recorded. When doxorubicin was added to the incubation buffer, inhibition of both contraction frequency and contractile force occurred. As shown in Fig. 8 , the catalase overexpressing atrium displayed a marked resistance to the toxic effect of doxorubicin. In addition, the function of the transgenic atrium completely recovered after removal of doxorubicin, but the normal atrium did not. To precisely determine the effect of doxorubicin on contractile force (inotropy) and heart rate (chronotropy), left and right atria were separated. The left atrium was paced by a stimulator at a fixed frequency of 4 Hz and a voltage of 1.5 times the threshold value. As shown in Fig. 9 , 60-fold elevation of catalase activity markedly suppressed doxorubicinreduced changes in inotropy (left atrium) and chronotropy (right atrium). DISCUSSION Cardiotoxicity has long been recognized as a complicating factor of cancer chemotherapy with doxorubicin. There are several hypotheses to explain doxorubicin cardiotoxicity. Among these the free radical hypothesis is the most thoroughly investigated. Doxorubicin undergoes one-electron reduction through a metabolic activation caused by NADPH-cytochrome-P-450 reductase, or other flavin-containing enzymes (30) . This reduction generates a doxorubicin semiquinone free radical. In the presence of molecular oxygen, the semiquinone rapidly reduces the oxygen to superoxide with regeneration of intact doxorubicin. Superoxide is rapidly converted to hydrogen peroxide spontaneously or by superoxide dismutase. The doxorubicin semiquinone can then react with the hydrogen peroxide to yield a hydroxyl radical (31) . These highly toxic reactive oxygen species react with cellular molecules including nucleic acids, protein, and lipids, thereby causing cell damage. Most supportive evidence for this free radical hypothesis has been obtained from in vitro studies including reports that: 1) doxorubicin increases lipid peroxidation and free radical production in the heart tissue (32); 2) free radical scavengers such as N-acetylcysteine (33), vitamin E (34), superoxide dismutase (34), and catalase (7) decrease the severity of doxorubicin-induced oxidative damage; 3) suppression of antioxidant activities enhances doxorubicin toxicity in cultured cardiac cells (35) . However, contradictory results have been reported. Some in vivo studies have shown that free radical scavengers failed to prevent cumulative doxorubicin cardiotoxicity (36, 37) .
Why have some in vivo studies failed to find antioxidant protection against doxorubicin cardiotoxicity? Under in vivo conditions, three major problems complicate data interpretation: 1) it is impossible to maintain constant plasma antioxidant concentrations and to accurately predict the target tissue concentrations; 2) metabolic activation and inactivation by multiple metabolic organs such as liver and kidney would greatly affect the efficacy of the antioxidants; and 3) high molecular weight antioxidants such as superoxide dismutase and catalase are unlikely transported into intracellular compartments. To overcome the shortcomings of these earlier in vivo studies, we produced a unique transgenic model in the present study. As described under "Results," in this model intracellular catalase activities are maintained at permanently elevated levels specifically in the heart of each transgenic line. Other antioxidant systems were found to be unaffected in the catalase overexpressing heart. Electron microscopic studies (data not shown) demonstrated increased numbers of peroxisomes in transgenic hearts, suggesting a significant amount of elevated catalase is contained in peroxisomes.
The results obtained from this study clearly demonstrate that elevation of catalase activity to an optimum level provides protection against doxorubicin-induced cardiac injury. This suggests that low catalase activity in the heart is a major factor responsible for the high sensitivity of the heart to doxorubicininduced damage. Because catalase is a major enzyme that metabolizes H 2 O 2 in the cell and this enzyme has no activity to react with doxorubicin and its metabolites, the results thus provide direct evidence to support the oxidative injury hypothesis for doxorubicin. Lipid peroxidation is a major cardiotoxic indicator of doxorubicin, particularly under the conditions of acute exposure. It has been found that doxorubicin more selectively induces this oxidative damage to the heart relative to other organs such as the liver in mice (38) . We have determined the lipid peroxide levels in the heart induced by doxorubicin as a function of time (days). We found that at the selected dose (20 mg/kg) lipid peroxide levels in the heart reach a peak value on the 4h day after the drug treatment (data not shown). This peak value coincides with high serum CPK activity at the same time, which is in agreement with previous studies (39) . Because the elevation in serum CPK results from the myocardial cell membrane damage due to lipid peroxidation, the increased serum CPK activity has been used as another indicator of FIG. 7 . Doxorubicin-induced CPK release from the heart. Serum CPK was measured using a CK-20 kit from Sigma. Sera from the same animals treated for determination of lipid peroxidation were collected for the CPK measurement. As shown, doxorubicin significantly increased serum CPK level in the nontransgenic control mice (DOX). Elevation of catalase in the heart to about 60-(line 742) or 100-fold (line 776) higher than normal completely inhibited the increase in the serum CPK level (p Ͻ 0.05). However, elevation of cardiac catalase activity to about 200-fold (line 777) higher than normal did not protect against this toxic effect of doxorubicin. doxorubicin-induced heart damage (39, 40) . The results obtained from this study show that elevated catalase activity protects from doxorubicin-induced lipid peroxidation, which correlates with the protection against CPK release. In both cases, 60-or 100-fold elevation of catalase activity provides maximum protection.
Functionality of the isolated mouse atrium has been increasingly used as a fast screening method for determination of cardiotoxicity induced by doxorubicin (41) . Usually, the mouse atrium is incubated with the tested compound and changes in inotropy (contractile force) and chronotropy (heart rate) are recorded as a measurement of cardiotoxicity. It has been shown that doxorubicin depresses the functionality of isolated mouse atria (42) (43) (44) . Doxorubicin-induced functional changes in the isolated atria were observed in the present study. Both contractile force and heart rate were suppressed. Sixty-fold elevation of catalase activity markedly depressed this effect of doxorubicin on cardiac function. This result demonstrates that doxorubicin-induced cardiac functional alterations most likely result from reactive oxygen species and that the severity of the functional alterations is associated with catalase levels.
In the present study we found that 200-fold elevation of catalase activity in the heart did not provide protection against doxorubicin toxicity and 500-fold elevation may even enhance the doxorubicin cardiotoxicity. The same observation has also been reported in vitro. For instance, transfection of L cells with a human catalase cDNA elevated catalase activity by 100-fold. These catalase-enriched cells, however, were more sensitive rather than resistant to the cytotoxicity of paraquat, bleomycin, and doxorubicin than the untransfected cells from which they were derived (45) . At least two mechanisms have been proposed for the increased sensitivity of the high catalase containing cells: 1) imbalance between SOD and catalase (46 -48) and 2) chelation of heme iron by catalase and release of iron after degradation of catalase. It has been shown that irondoxorubicin complex is toxic (49) . The relevant mechanism for the effect observed in our mice is uncertain at this time.
The transgenic model produced in this study will provide a valuable experimental approach to understanding mechanisms of other cardiac disease conditions. There is, for example, disagreement on whether ischemia-reperfusion-induced heart damage is mediated by oxidative stress and whether low catalase activity in the heart generally makes the heart more sensitive to a variety of oxidative injuries. This experimental model should provide a means to test these related hypotheses.
FIG. 9. Effect of catalase elevation on doxorubicin-reduced inotropy (A, left atrium) and chronotropy (B, right atrium).
The transgenic atria (line 742) contain catalase activity about 60-fold higher than the nontransgenic control and doxorubicin was added into the incubation buffer to a final concentration of 100 M. The left atria were paced by a fixed frequency of 4 Hz and a voltage of 1.5 times the threshold value. This measurement was repeated three times with atria isolated from different animals and consistent results were obtained.
